Skip to main content
VCEL
NASDAQ Life Sciences

Vericel Beats on Q3, Raises 2026 Revenue Guidance to $344-$346M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$48.89
Mkt Cap
$2.329B
52W Low
$28.95
52W High
$49.32
52W Position info
69% above low
Off High info
at 52W high
Rel. Volume info
3.3× avg
Market data snapshot near publication time

VCEL sits 69% above its 52-week low of $28.95 on elevated volume (3.3× avg).

Summary

Vericel reported Q3 revenue of $85.4M (up 26%) and net income of $14.2M (up 179%), then raised full-year revenue guidance to $344-$346M and its adjusted EBITDA margin target to 28%.


Key Events · Earnings and Guidance · VCEL

  • Q3 Revenue Up 26% to $85.4M

    MACI revenue rose 21% to $67.4M and Burn Care rose 52% to $18.0M, including $3.0M of BARDA procurement revenue.

  • Net Income Up 179% to $14.2M

    Diluted EPS was $0.27 versus $0.10 a year ago; adjusted EBITDA rose 48% to $25.2M, or 30% of revenue.

  • Full-Year Guidance Raised

    Revenue guidance lifted to $344-$346M from $330-$340M; Burn Care to $54M from $46-$50M; adjusted EBITDA margin to 28% from 27%.

  • Buyback Continues

    Repurchased 220,744 shares for $8.8M in Q3, with $191.2M of authorization remaining as of September 30, 2026.


Analysis · VCEL · Life Sciences

Vericel's Q3 revenue grew 26% to $85.4M and net income jumped 179% to $14.2M ($0.27 per diluted share), with adjusted EBITDA at 30% of revenue. Management raised full-year revenue guidance to $344-$346M from $330-$340M and lifted the adjusted EBITDA margin target to 28% from 27%, citing a strong start to Q4 in both MACI and Burn Care. The company also bought back 220,744 shares for $8.8M in the quarter, leaving $191.2M of authorization, and holds $235.6M in cash and investments with no debt. The stock is trading near its 52-week high of $49.32, so the raised guidance is the key test of whether that level holds.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VCEL was trading at $48.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $28.95 to $49.32. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VCEL - Latest Insights

VCEL
Nov 05, 2026, 8:56 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $49.00
Real-time Price: $58.00 info
Change: +$9.00 (+18%) info
Market Cap: $2.973B info
VCEL
Nov 05, 2026, 7:55 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $45.48
Real-time Price: $58.00 info
Change: +$12.52 (+28%) info
Market Cap: $2.973B info
VCEL
Jul 30, 2026, 8:49 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $48.59
Real-time Price: $58.00 info
Change: +$9.41 (+19%) info
Market Cap: $2.973B info
VCEL
Jul 30, 2026, 8:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $48.59
Real-time Price: $58.00 info
Change: +$9.41 (+19%) info
Market Cap: $2.973B info
VCEL
Jul 30, 2026, 7:55 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $48.59
Real-time Price: $58.00 info
Change: +$9.41 (+19%) info
Market Cap: $2.973B info